APP
ALLO icon

Alpha Paradigm Partners’s Allogene Therapeutics ALLO Stock Holding History

Alpha Paradigm Partners’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,966
Closed -$128K – 533
2021
Q3 		$128K Buy
+4,966
New +$118K 0.05% 396

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Alpha Paradigm Partners's ALLO Position: Q4 2021 in Review

Alpha Paradigm Partners sold out of Allogene Therapeutics (ALLO) in Q4 2021, closing a stake of 4,966 shares — an estimated $128K sold.

Alpha Paradigm Partners first reported a position in ALLO in Q3 2021 and held it in 1 quarter. The position peaked at $128K in Q3 2021. 177 funds tracked by Wall St. Rank hold ALLO as of Q4 2021.

  • Alpha Paradigm Partners reported no remaining Allogene Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Alpha Paradigm Partners sold 4,966 Allogene Therapeutics shares in Q4 2021, an estimated $128K.
  • Alpha Paradigm Partners first reported a position in Allogene Therapeutics in Q3 2021 and held it in 1 quarter.
  • Alpha Paradigm Partners's Allogene Therapeutics position peaked at $128K in Q3 2021.
  • 177 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2021.

Based on Alpha Paradigm Partners's 13F filing for Q4 2021, filed 14 Feb 2022.